Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (498)	1/29/2004 3:28:20 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ELN Made a 52 wks. H this morning when it traded at 9.15 ( above its January 22 H of 9.12) It was helped by the announcement that the PIII trial of ANTEGREN in Crohn's met the primary endpoint of maintenance of response by a CDAI score of less than 220 and no use of rescue intervention throughout 6 months of the trial. There was more than 30% difference in favor of the ANTEGREN treated patients and no significant difference in side effects. The support is at 7.85 and nearest resistance at today's H. bigcharts.marketwatch.com The stock has some room to run, but there is a good amount of resistance ahead.<g> bigcharts.marketwatch.com Bernard